神经科

订阅

MedSci主页 / 所有栏目 / 神经科

阿尔茨海默症治疗再遇挫折：Eisai和Biogen终止了BACE抑制剂elenbecestat的研发

2019-09-14 Allan MedSci原创

BACE抑制剂elenbecestat阿尔茨海默症
关注

Eisai和Biogen近日表示，他们将结束实验性口服BACE抑制剂elenbecestat的III期研究，elenbecestat预计用于治疗阿尔茨海默症早期患者。

Eisai和Biogen近日表示，他们将结束实验性口服BACE抑制剂elenbecestat的III期研究，elenbecestat预计用于治疗阿尔茨海默症早期患者。两家公司指出，该决定是在数据安全监督委员会进行的安全审查之后作出的，该委员会建议，鉴于不利的风险 - 收益比率，需要停止试验。

elenbecestat的后期计划包括两项具有相同方案的临床试验（MISSION AD1和MISSION AD2），其共纳入约2100例患有轻度认知功能障碍或轻度阿尔茨海默症的患者，并在脑中确认了淀粉样蛋白病变。在24个月的治疗期间，患者被随机分配接受elenbecestat或安慰剂。两家公司表示，研究的详细结果将在未来的医学会议上公布。


原始出处：

http://www.firstwordpharma.com/node/1666114#axzz5zU18ApSM

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-01-09 12498da4m32(暂无昵称)

    #阿尔茨海#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-11-04 shanyongle

    #ACE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-02-12 oliver169

    #BACE抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-01-30 ms1948154235210413

    #阿尔茨#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-10-12 zhouqu_8

    #EST#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-02-21 sunylz

    #Bio#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2020-06-06 jklm09

    #抑制剂#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 lqvr

    #研发#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 qjddjq

    #Biogen#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1817962, encodeId=4de5181e9624a, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Thu Jan 09 22:21:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655970, encodeId=cdbb16559e0b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Mon Nov 04 16:21:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978064, encodeId=07b419e8064c6, content=<a href='/topic/show?id=e63a31596d' target=_blank style='color:#2F92EE;'>#BACE抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3159, encryptionId=e63a31596d, topicName=BACE抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Feb 12 14:21:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816939, encodeId=456f1816939d0, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Jan 30 01:21:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051439, encodeId=e6cc2051439d1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Oct 12 03:21:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918851, encodeId=6ddd1918851fc, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Feb 21 22:21:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852124, encodeId=9b59185212441, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jun 06 07:21:00 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300305, encodeId=85e3130030508, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404337, encodeId=be10140433ec5, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470316, encodeId=e22614e031615, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Mon Sep 16 07:21:00 CST 2019, time=2019-09-16, status=1, ipAttribution=)]
    2019-09-16 yhj-time

    #阿尔茨海默#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

肝脏安全问题促使强生公司放弃BACE抑制剂atabecestat的研发

强生公司表示，将终止对晚发性临床前阶段阿尔茨海默病患者开发BACE抑制剂atabecestat的研发。该公司指出，这一决定是在某些接受该药物的患者中观察到肝酶升高后决定的，这些肝酶问题是“性质严重”的

BACE抑制剂——阿尔茨海默（AD）新药研发舞台中心的翩翩舞者

阿尔茨海默氏症（AD）一直是新药研发的重灾区，该领域研发失败率高达99.6%，许多在早期研发阶段极具潜力的药物在III期临床均惨遭失败，其中包括辉瑞/强生和礼来各自投资超过10亿美元的单抗药物bapineuzumab和solanezumab。而2年前罗氏单抗gantenerumab在大型III期临床中惨败，使得AD领域的新药研发更加雪上加霜。之后，另一个很有前途的新药类别——BACE抑制剂，成功取